Anti-™EM183A monoclonal antibody

Pre-made anti-™EM183A monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to ™EM183A/™EM183A products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP2023-Ab-1/ GM-Tg-hg-IP2023-Ab-2Anti-Human ™EM183A monoclonal antibodyHuman
GM-Tg-rg-IP2023-Ab-1/ GM-Tg-rg-IP2023-Ab-2Anti-Rat ™EM183A monoclonal antibodyRat
GM-Tg-mg-IP2023-Ab-1/ GM-Tg-mg-IP2023-Ab-2Anti-Mouse ™EM183A monoclonal antibodyMouse
GM-Tg-cynog-IP2023-Ab-1/ GM-Tg-cynog-IP2023-Ab-2Anti-Cynomolgus/ Rhesus macaque ™EM183A monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP2023-Ab-1/ GM-Tg-felg-IP2023-Ab-2Anti-Feline ™EM183A monoclonal antibodyFeline
GM-Tg-cang-IP2023-Ab-1/ GM-Tg-cang-IP2023-Ab-2Anti-Canine ™EM183A monoclonal antibodyCanine
GM-Tg-bovg-IP2023-Ab-1/ GM-Tg-bovg-IP2023-Ab-2Anti-Bovine ™EM183A monoclonal antibodyBovine
GM-Tg-equg-IP2023-Ab-1/ GM-Tg-equg-IP2023-Ab-2Anti-Equine ™EM183A monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP2023-Ab-1/ GM-Tg-hg-IP2023-Ab-2; GM-Tg-rg-IP2023-Ab-1/ GM-Tg-rg-IP2023-Ab-2;
GM-Tg-mg-IP2023-Ab-1/ GM-Tg-mg-IP2023-Ab-2; GM-Tg-cynog-IP2023-Ab-1/ GM-Tg-cynog-IP2023-Ab-2;
GM-Tg-felg-IP2023-Ab-1/ GM-Tg-felg-IP2023-Ab-2; GM-Tg-cang-IP2023-Ab-1/ GM-Tg-cang-IP2023-Ab-2;
GM-Tg-bovg-IP2023-Ab-1/ GM-Tg-bovg-IP2023-Ab-2; GM-Tg-equg-IP2023-Ab-1/ GM-Tg-equg-IP2023-Ab-2
Products NameAnti-™EM183A monoclonal antibody
Formatmab
Target Name™EM183A
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-™EM183A monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP2023-Ag-1Recombinant multi-species T183A/ ™EM183A/ C1orf37 protein


    Target information

    Target IDGM-IP2023
    Target Name™EM183A
    Gene ID92703,57439,289034,704195,479994,101100026,534797,100065104
    Gene Symbol and Synonyms1300007B12Rik,1700020N19Rik,C1orf37,RGD1309892,Tmem183,™EM183A
    Uniprot AccessionQ8IXX5,Q68FS7,Q5EA86
    Uniprot Entry NameT183A_HUMAN,™183_RAT,™183_BOVIN
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000163444
    Target ClassificationN/A

    The target: ™EM183A, gene name: ™EM183A, also named as C1orf37. Predicted to be involved in regulation of protein stability. Predicted to be integral component of membrane. Predicted to be part of SCF ubiquitin ligase complex. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.